Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Completed · Phase 3 · Has a placebo group

Conditions studied: Keratoconus

In brief

A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Key facts

Study ID

NCT06100939

Run by

Epion Therapeutics

People needed

396

Starts

2023-10-30

Expected to finish

2026-06-12

Last updated by the study team

2026-06-25

Who can join

Age: 8 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of keratoconus

You may not qualify if…

• Minimal corneal thickness < 350 microns
• Non-keratoconic ectatic disease
• Contraindications or hypersensitivities to any required study medications
• Pregnancy or breastfeeding
• Certain concomitant ocular conditions

Where it is running

• Nvision Eye Centers Rowland Heights — Rowland Heights, California, United States
• Goodman Eye Center — San Francisco, California, United States
• Center for Excellence in Eye Care — Miami, Florida, United States
• Chicago Cornea Consultants — Hoffman Estates, Illinois, United States
• Boston Vision — Brookline, Massachusetts, United States
• Ophthalmology Associates — St Louis, Missouri, United States
• The Eye Doctors at CNY Eye Care — East Syracuse, New York, United States
• Cincinnati Eye Institute — Cincinnati, Ohio, United States
• Devers Eye Institute — Portland, Oregon, United States
• Wills Eye Hospital — Philadelphia, Pennsylvania, United States
• UPMC Vision Institute — Pittsburgh, Pennsylvania, United States
• Baylor College of Medicine — Houston, Texas, United States
• University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.